BACKGROUND The PiB compound has been promising for detection of amyloid deposits in the brain.
for imaging b-amyloid in Alzheimer's disease (6) and is believed to bind to amyloid fibril of any type (7) .
We expected positron emission tomography (PET) imaging using this compound to be a promising choice for imaging cardiac amyloidosis, the preliminary results of which has been successful in a small case series (8) . In this pilot study, we present the analysis results of a prospective cohort of cardiac amyloidosis patients examined using the 11 C-PiB PET/ computed tomography (CT) scan, together with cardiac magnetic resonance (CMR), echocardiography, and endomyocardial biopsy.
METHODS
A detailed version of the Methods section is described in the Online Appendix.
PATIENT POPULATION. A total of 27 patients were consecutively assessed for eligibility to this prospec- was divided further into a chemotherapy naïve group versus the previous chemotherapy group according to whether the patient had undergone previous chemotherapy before the 11 C-PiB PET/CT scan.
In addition, we enrolled 10 normal subjects (4 males, age range 37 to 80 years) without any evidence of heart disease to determine the cut-off value of the positive 11 C-PiB PET/CT scan. To determine the optimal cut-off value of 11 C-PiB PET/CT, we analyzed the images of 10 sex-matched normal subjects ( Table 1) . As the amyloid protein deposit may be heterogeneous (9), the cut-off value was determined with the maximal rather than the mean LV myocardium to blood cavity ratio. The maximal LV myocardium to blood cavity ratio did not exceed 1.6 in all control subjects. In addition, 2 weeks later, intraobserver variability of the maximal LV myocardium to blood cavity ratio in these patients did not exceed 0.2 in all subjects. Therefore, 
RESULTS
A total of 22 patients were enrolled in this prospective pilot study, among whom 15 patients were diagnosed with cardiac amyloidosis using tissue confirmation by endomyocardial biopsy. Baseline clinical characteristics of these patients are summarized in Table 2 . In the biopsy-proven cardiac amyloidosis group, the median age of the patients was 64 years, and 7 patients were male. Patients #1 to #15 were diagnosed with cardiac amyloidosis by positive Congo red staining and amyloid P staining on endomyocardial biopsy. The immunostaining of the endomyocardial biopsy samples were also matched with the serum free light chain assay results. All patients had AL amyloidosis, and there were no patients diagnosed with senile amyloidosis. The maximal SUV was defined as the maximal SUV in all of the VOIs analyzed. The mean SUV was defined as the mean SUV of the total voxels in the VOIs. The maximal/mean myocardium to blood cavity ratio was defined as the maximal/mean SUV of the myocardial VOIs divided by the mean SUV of the descending thoracic aorta VOIs.
CT ¼ computed tomography; LV ¼ left ventricular; PET ¼ positron emission tomography; PiB ¼ Pittsburgh B; SUV ¼ standard uptake value; VOI ¼ volume of interest.
A detailed description on the amyloidosis status of the enrolled patients is summarized in Table 2 The echocardiography data for all study participants are summarized in Table 3 . There were no Individual clinical and 11 C-PiB PET/CT results of the study participants are listed. All patients were diagnosed with cardiac amyloidosis by positive Congo red and amyloid P immunohistochemical staining on endomyocardial biopsy. The immunostaining of the endomyocardial biopsy samples were also matched with the serum free light chain assay results. A cutoff value for positive versus negative 11 C-PiB PET/CT was defined as maximal myocardium-to-blood cavity ratio $2.0 on the basis of results of control subjects in Table 1 . The difference between the involved and uninvolved free light chain levels is shown in the DFLC column with k and l levels in the parenthesis, respectively. #n indicates number of cycles of chemotherapy.
ECG ¼ electrocardiogram; FLC ¼ free light chain; MD ¼ melphalan þ dexamethasone; PBSCT ¼ peripheral blood stem cell transplantation; TD ¼ thalidomide þ dexamethasone; other abbreviations as in Table 1 . Values are median (range) or % (n). The echocardiography was done at the time of enrollment. The e 0 velocity was measured at the septal side of the mitral annulus.
LV ¼ left ventricular. Figure 1D] ). It was also notable that the degree of mean RV uptake was proportionate to the degree of mean LV uptake (Spearman's r ¼ 0.912, p < 0.001 between mean LV vs. mean RV myocardium to blood cavity ratio) ( Figure 1E ). Figure 2D) . The 11 C-PiB uptake pattern was mainly diffuse and homogeneous at the LV as well as the RV (Figure 2A, patient 9 ).
However, in some cases, the hot uptake was more striking at localized areas such as the septal and lateral segments ( Figure 2B, patient 5) . Although the maximal LV myocardium to blood cavity ratio was numerically higher in the cardiac amyloidosis patients who had undergone previous chemotherapy, the 11 C-PiB uptake was only marginally stronger in the cardiac amyloidosis patients who had undergone previous chemotherapy ( Figure 2C ) compared with the patients without cardiac amyloidosis ( Figure 2D) on visual inspection.
The gadolinium-enhanced CMR was not performed in 3 patients in the 11 C-PiB PET/CT-negative group because of significant azotemia (creatinine clearance #30 ml/kg/min). Diverse patterns of LGE were noted in the patients, ranging from no LGE, to a more typical subendocardial ring enhancement, and to a LGE-CMR image was also normal. Abbreviations as in Figure 1 .
Lee et al. Table 5) .
Overall, the sensitivity and specificity of sults. In support of this, it has been reported in a previous study that the probability of a false-negative CMR may be approximately 12% in a biopsy-proven cardiac amyloidosis (21) . Also, the case of Patient #8
demonstrates the unique opportunity of 11 C-PiB PET/ CT for the diagnosis of cardiac amyloidosis in the setting of significant azotemia, a situation where contrast-enhanced CMR cannot be performed (22) .
The true importance of our study is that quantitative assessment of amyloid deposit might be possible by using 11 C-PiB PET/CT in cardiac amyloidosis. The test results indicate that there is potential for the use we were able to quantify the SUV of the myocardium using the 11 C-PiB PET/CT. Especially, considering that the majority of the patients who had undergone previous chemotherapy had at least a partial response to the treatment, the striking difference of 11 C-PiB uptake between the chemotherapy naïve group and the previous chemotherapy group suggests that the 11 CPiB PET/CT results may reflect active deposition of amyloid protein in the myocardium. Further investigations in a larger population and follow-up scans may give further insight into the mechanism of the isotope uptake.
STUDY LIMITATIONS. First, the small number of patients makes some findings of our study difficult to generalize. Furthermore, all of our patients had AL amyloidosis, and whether our findings extend to other causes of cardiac amyloidosis, such as senile or hereditary amyloidosis, needs further observation. In this aspect, it is interesting to note that 11 C-PiB PET was valuable for the diagnosis of transthyretinassociated senile amyloidosis in a previous study (8) .
Second, we cannot provide data as to whether the myocardium to blood cavity ratio of 11 C-PiB is related to myocardial blood flow. However, all except 1 patient were void of any history of coronary artery disease, and a previous report has also demonstrated that the retention index of 11 C-PiB is unrelated to quantified myocardial blood flow (8) . Third, we did not perform dynamic PET scans as in a previous study (8) .
However, we aimed to develop a relatively simple method that would be ready for clinical usage, an objective difficult to achieve with the kinetic model.
Furthermore, the tissue to blood pool ratio tends to increase after 20 min post-injection (10), and we assumed that 30 min post-injection may be a sufficient time point to measure the tissue to blood pool ratio.
Last, the current sample number may not be sufficient to make a reasonable comparison of the diagnostic performance between 11 C-PiB PET/CT and CMR.
CONCLUSIONS
We have shown in this pilot study that 11 C-PiB PET/CT may be valuable for noninvasive diagnosis of cardiac amyloidosis. Additionally, the significant difference 
